Antiretroviral drug supply challenges in the era of scaling up ART in Malawi by Schouten, Erik J et al.
Background
Th   e number of people receiving antiretroviral treatment 
(ART) has increased considerably in recent years to reach 
approximately 5.25 million by the end of 2009 [1]. Th  e 
majority of patients on ART (3.9 million) live in sub-
Saharan Africa. Despite the impressive growth, ART 
coverage of the population in need, calculated on the 
basis of the 2010 World Health Organization (WHO) 
guidelines [2], is 37% for adults and 28% for children, and 
in eastern and southern Africa, 41% for adults and 32% 
for children [1]. With an unabated growth of ART 
cohorts managed at an ever-increasing number of facili-
ties, procurement and supply chain management (PSM) 
systems for HIV/AIDS medicines in resource-con-
strained countries are facing unprecedented challenges, 
and ruptures of the PSM systems are becoming a growing 
concern.
A WHO survey in 2009 revealed that 36 (38%) out of 
94 reporting countries had documented at least one 
stock out of antiretroviral (ARV) drugs in health 
facilities [1]. Interrupted supply of ARVs puts individual 
patients at risk of disease progression and death [3], 
jeopardizes public health due to development of ARV 
drug resistance, hampers progress towards universal 
access, and dimin  ishes the credibility of ART pro-
grammes in the eyes of patients, the community and 
healthcare providers. An increase and spread of HIV 
drug resistance will neces  sitate a change of ﬁ  rst-line 
ARV regimens, and these are without exception more 
expensive and increase the costs of national ART 
programmes. In Malawi, the number of people on ART 
is expected to double, from 250,000 in December 2010 
to more than 500,000 by June 2015, and the number of 
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than 700 [4].
Th  is article will discuss operational challenges and 
operational research directions around the management 
and prevention of stock outs of ARVs in Malawi, a low-
income country in southern Africa with a weak PSM and 
health system.
ARV drug supply management system in Malawi
In many low- and middle- income countries, the capacity 
of the PSM systems has always been weak [5]. Th  e 
management of supplies for what is essentially a chronic 
disease needing lifelong therapy is becoming increasingly 
diﬃ   cult with further scale up of HIV care and treatment.
Responsibility for procurement and distribution
During the design of the plan for the national roll out of 
the ART programme in Malawi, the weakness of the PSM 
system was well understood, and the challenge for the 
HIV programme managers was to establish a PSM system 
for ARVs that performed better than the general existing 
supply management systems. Th   e debate about whether 
to improve the national PSM system as part of the HIV 
programme design or to develop a parallel PSM system 
for ARVs was overtaken by events because in 2002, a 
World Bank mission advised that the government Central 
Medical Stores should not be used for the procurement 
of HIV and AIDS supplies with funding from the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (the 
Global Fund) [6]. Th  e United Nations Children’s Fund 
(UNICEF) was proposed instead, and UNICEF, through 
its supply division in Copenhagen, Denmark, has been 
procuring and distributing ARVs in Malawi since 2004.
Public health approach
Malawi’s Ministry of Health worked together with 
partners, including UNICEF, to develop the PSM system 
for ARVs that has been in place since 2004. Th  e  system 
has functioned relatively well and there have been no 
major stock outs of ARVs in Malawi, unlike many other 
medicines and medical supplies. It was clear from the 
onset of the national ART programme that it could only 
be successful if it was based on the realities in the health 
sector, in other words, by following a public health 
approach, i.e., a simpliﬁ  ed, standardized and structured 
approach [7].
Th  e ﬁ  rst two years of experience have been reported 
earlier [8] and, here, we brieﬂ  y describe the model.
National, simple and standardized
At the outset in 2004, the ART programme focused on 
the roll out of one ﬁ  rst-line ART regimen using a ﬁ  xed-
dose generic combination of stavudine, lamivudine and 
nevirapine. Th   is regimen was the only one available in all 
but a few health facilities in the country providing ART 
services. Two alternative ﬁ  rst-line ARV regimens (in case 
of toxicity) and a second-line ARV regimen (in case of 
treatment failure) were available in only four ART clinics 
in the country.
ARVs were distributed using a pre-packed kit system 
with “starter packs” and “continuation packs”, which 
simpliﬁ   ed the supply management [8]. Using this 
approach, the ART programme was scaled up quickly and 
without any drug stock outs in its ﬁ  rst four years [7].
A “push system” and “ceilings” for the number of new 
patients starting ART
To ensure some control on rational drug forecasting for 
new patients, ART sites were given a ceiling of the 
maximum number of patients they were allowed to start 
each month on treatment. Th  ese ceilings were estab-
lished on the basis of the number of inpatient beds, the 
population served, HIV prevalence and tuberculosis case 
burden (serving as a proxy for HIV/AIDS burden, given 
the strong association between the two diseases). Th  e 
ceilings could be (and were frequently) adapted to cater 
for a higher demand and available capacity to provide 
ART, but only after the additional drug supplies were in 
place. Th   ese ceilings allowed easy calculations to be made 
on the number of “starter packs” needed for each site.
Quarterly monitoring of patient outcomes and ARV drug 
stocks
At the end of every quarter, cumulative treatment 
outcomes of all patients started on ART at each site and 
the number of patients retained alive and on treatment 
were recorded. Th  is latter count (patients alive and on 
treatment) captured the number needing continuation 
therapy, which needed to be added to the number of new 
patients starting treatment. ARV stocks were also 
counted in the pharmacies, and these data allowed a 
system of rational drug forecasting to be put in place to 
calculate the number of “continuation packs” needed for 
each site.
Using a parallel procurement and distribution system for 
ART
Th  e PSM system for ARVs was set up in parallel to the 
government’s PSM system run through Central Medical 
Stores. It was, and still is, characterized by a centrally 
coordinated quantiﬁ  cation on the basis of veriﬁ  ed data 
from all ART clinics in the country, procurement through 
UNICEF’s supply division and direct distribution of drugs 
to ART clinics, bypassing Central Medical Stores. 
Distribution of a six-month supply of ARVs to ART 
clinics was planned to take place when remaining drug 
stocks were estimated to be equivalent to two months of 
consumption.
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research areas
As the national ART programme has grown, it has 
become clear that the ARV PSM system based on the 
tenets we have outlined has become increasingly diﬃ   cult 
to manage. Th   is is due to a number of reasons, such as 
increasing numbers of people on ART, increasing 
numbers of sites providing ART, and a greater diversity of 
diﬀ  erent ARV regimens. We will describe the challenges 
faced since the early years of the model and possible 
solutions or research needed to strengthen the system 
and avoid ARV stock outs.
ARV drug regimes
By the end of December 2010, 91% of patients were still on 
the standard ﬁ  rst-line regimen [9]. However, the number 
of diﬀ  erent ARV formulations available to primary level 
ART sites has increased over the years to nine, and in the 
whole programme to 19 (11 adult and eight paediatric). 
Moreover, tertiary ART clinics and non-governmental 
organizations have been requesting an increase in the 
number of formulations to provide more individualized 
care; some specialized private and non-governmental ART 
clinics use a larger number of ARV formulations.
It is clear that in a growing and maturing ART pro-
gramme, the very limited number of ARVs used during 
the ﬁ   rst years of the national programme cannot be 
maintained and a balance needs to be found between 
improving individual care and maintaining a well-
functioning PSM system. To better inform this debate 
and national policy, cost-eﬀ  ectiveness studies could be 
carried out to compare sites using many diﬀ  erent ARV 
formulations with the national programme.  Such 
research would also be useful as a guide to other 
countries that may be struggling with this balance.
Patient ceilings and forecasting
Th  e system of patient ceilings helped to prevent stock 
outs in the ﬁ  rst years of the programme. However, as the 
numbers of people on ART increased, the bulk of the 
ARV consumption shifted to patients already on ART 
and away from patients who were newly starting 
treatment. Th  e system of ceilings therefore became 
superﬂ   uous. Programme managers also became more 
experienced in more accurately forecasting the number 
of people on ART and ARV supplies needed. However, 
the number of people shifting to alternative ﬁ  rst-line 
ART regimens (for reasons of drug toxicity) and second-
line ART (for reasons of treatment failure) has been more 
diﬃ   cult to predict. Th   is led at one time to over-supply of 
second-line ARVs and contributed to shortages and even 
site stock outs of alternative ﬁ  rst-line ARVs, although the 
main factor for the stock outs were bottlenecks in the 
Global Fund grant disbursement.
Th   ese shortages have inﬂ  uenced the erratic growth of 
the number of people on these regimens (Figure 1) and 
made forecasting of supplies needed more complicated. 
A potential area for operational research could be, 
therefore, the development and testing of models to 
predict the proportion of patients on treatment who need 
ARV substitution because of toxicity or switching due to 
treatment failure to help improve forecasting of second-
line and alternative ARV consumption.
Procurement processes
Th   e traditional PSM system of providing health facilities 
with a consignment of supplies to ensure that stock 
positions in health facilities are maintained within the set 
range of “minimum-maximum stock position”, based on 
an average monthly consumption calculated using past 
consumption, does not work for ARVs as the patient 
burden grows and the consumption continually increases. 
Th   e Global Fund requires that all ARVs are accounted for, 
and thus Malawi set up a monitoring and evaluation 
system in which patient data are audited and physical 
stock checks are performed by a supervision team 
visiting all ART clinics on a quarterly basis [10].
UNICEF is requested by the Ministry of Health to 
prepare “cost estimates” for the required supplies. Once 
these have been received, the ministry veriﬁ  es the “cost 
estimates” and contacts the Principal Recipient of the 
Global Fund grant, the National AIDS Commission, to 
prepare a Disbursement Request to the Global Fund. Th  e 
Local Funding Agency performs some checks to verify if 
the request is correct, following which the Disbursement 
Request is sent to the Global Fund for ﬁ  nal approval. 
Once this has been obtained, the monies are transferred 
to UNICEF’s Supply Division and “purchase orders” are 
issued.
ARV shipments usually arrive some four months after 
the purchase orders have been placed, depending on the 
manufacturers’ production capacity and air transport to 
Malawi. Supplies are then distributed by UNICEF to 
health facilities within a month after arrival in country. 
Th   e process from quantiﬁ  cation to receipt of supplies at 
the health facilities is complex, lengthy and involves 
multiple players (Figure 2). Orders of ARVs that are made 
on the basis of stock positions and the number of people 
on ART at the end of June 2011 will not arrive in health 
facilities before May 2012, almost one year later.
Th   e long procurement process and increasing quantity 
of ARVs pose major challenges to prevent stock outs. 
First, predictions have to be made for one year ahead. 
While a degree of conﬁ  dence is applied around some of 
the estimates for each site, with an obvious tendency to 
over-order instead of under-order, it may be necessary to 
increase the in-country stocks of ARVs to cover the 
eventuality of potential delays in the process.
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operates without a central warehouse and a national 
buﬀ  er stock, which diminishes the in-country capacity to 
prevent stock-outs of ARVs. Th  e buﬀ  er stock, or safety 
stock, is the minimum stock that is kept on hand to 
protect against stock out. If there is no safety stock, stock 
outs will occur when deliveries are delayed or when there 
is an unexpected increase in demand [11]. As the ART 
programme has grown, the quantity of ARVs stored in 
health facilities has increased, sometimes beyond 
capacity. Th  ere is therefore a pressing need to have a 
central warehouse facility. Th   is would need to be properly 
managed to ensure that stored drugs do not pass their 
expiry dates.
Th   ird, if a warehouse was set up, the option of having a 
national buﬀ  er stock would become feasible. Experience 
in Malawi has shown that once the national stock 
position (which reﬂ  ects all stock now available and soon 
to be available, including stock on hand and outstanding 
orders [11]) drops below two months of consumption 
(based on drug stock data collected from all national 
ARV sites), the prevention of stock outs becomes very 
diﬃ   cult, and a lot of time and energy is put into re  distri-
bution of supplies. We believe that the establishment of a 
national buﬀ  er stock that would maintain the national 
stock position at six months’ consumption is a priority. 
Such a proposal has been put forward to the Global Fund, 
who has agreed to fund it.
Fourth, plans have been developed to increase the 
frequency of distribution to health facilities from six 
monthly to three monthly to reduce the average quantity 
of ARVs held in health facilities; however, this cannot 
happen until a central warehouse and a national buﬀ  er 
stock are established. More frequent distributions will 
not only reduce the pressure on storage space in health 
facilities, but also facilitate the response to unexpected 
changes in demand as redistributions take place between 
health facilities.
Institutionalization of the PSM system for ARVs
Th   e work of keeping the PSM system for ARVs on track is 
currently in the hands of very few people in the 
Department of HIV and AIDS in the Malawi Ministry of 
Health (monitoring and evaluation oﬃ   cer, HIV care and 
treatment oﬃ   cers) and the National AIDS Commission 
(director of ﬁ  nance, chief procurement oﬃ   cer), who spend 
only part of their time on supply management. Th  e  value 
of the ARVs for the national ART programme will increase 
from US$60 million per year in 2011 to $100 million in 
2015. Th  e value of these supplies is high in comparison 
with the government’s contribution to health, which was 
estimated at US$65 million in 2006 [12].
Figure 1. Number of patients on standard fi  rst-line (d4T/3TC/NVP), alternative fi  rst-line (AZT/3TC/NVP), alternative fi  rst-line 
(d4T/3TV/EFV), alternative fi  rst-line (AZT/3TC/EFV), second-line regimen and other regimens between 2005 and 2010 in the national 
ART programme in Malawi.
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Page 4 of 8Figure 2. Outline of the steps involved in procurement of ART drugs, from quantifi  cation by the Ministry of Health to the receipt of 
supplies at the health facilities.
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priately qualiﬁ  ed team, including staﬀ   from the Central 
Medical Stores, dedicated to procurement and supply 
management for ARVs and other HIV commodities, 
possibly combined with the procurement of other 
supplies procured with Global Fund monies. Th  is team 
would need to take full responsibility, and be accountable, 
for procurement and distribution. Once such a team was 
in place, it would be important to carry out operational 
research to document whether this led to a reduction in 
the quantity of ARVs expiring and the frequency of (near) 
stock outs of ARVs in health facilities.
Dependency on a single donor for drug ordering and 
procurement
Adequate funding for ARVs is a conditio sine qua non. 
Paying for ARVs by patients is associated with higher loss 
to follow up [13] and poorer treatment outcomes, and 
WHO advises therefore that ART should be free of 
charge in low- and middle-income countries [14]. 
Countries with a small economy, like Malawi, are not able 
to contribute signiﬁ  cantly to the procurement of ARV 
supplies. Malawi’s gross domestic product is US$318 (per 
capita) [15] and the government contribution to health 
was approximately US$65 million ($5.4 per capita) in 
2005-2006. Th   is is insuﬃ   cient to procure a considerable 
proportion of the annual need of ARVs.
Th  e vast majority of ARVs are procured with funds 
from the Global Fund and the lack of existing alternative 
funding sources makes the programme very susceptible 
to any bottlenecks in grant disbursement. Unforeseen 
delays in the PSM system over the past two years has 
led to periods of very low ARV stock levels, and even a 
few episodes of stock outs in a small number of health 
facilities. Most of these episodes were related to the late 
disbursement of funds, and virtually all steps prior to 
the disbursement of funds (see Figure 2) have contri-
buted at least once to these delays. As a ﬁ  rst step, it is 
important for all stakeholders to agree on what are the 
key steps and bottlenecks required to move a drug order 
through to drug distribution in the ﬁ  eld, and then to 
ﬁ  nd potential solutions to these barriers. Time-related 
targets should be set for each step, and then operational 
research should be conducted every six months to 
determine if targets were reached and reasons for not 
reaching targets.
Another recent and interesting development is the 
establishment by the UN Foundation of the “Pledge 
Guarantee for Health” to help grant recipients to 
accelerate health commodity procurement. Th  e pledge 
will support a bank to issue a letter of credit to a supplier 
on behalf of a grant recipient, which in principle should 
facilitate and speed up the procurement of supplies [16]. 
Th   is mechanism has yet to be used.
Changes in recommended ART regimens
WHO launched revised guidelines for prevention of 
mother to child transmission and ART in 2010 [2,17]. 
Th   ese guidelines advise changing the eligibility criteria to 
start ART and propose a move away from stavudine-
containing ART regimens to regimens with less toxicity. 
Th  e number of people eligible for ART increases by an 
estimated 45%, and the recommended ARV regimens are 
at least twice as expensive in comparison with the 
stavudine-containing regimens. Any associated changes 
in national recommendations as a result will require 
careful monitoring to ensure that past regimens will still 
be used until the stock is ﬁ  nished and before the expiry 
date and that the new regimen will be available in 
suﬃ   cient quantities to cover the needs (with progressive 
inclusion on new regimens). Malawi will then move on 
changing the ARV regimens.
Th  is process, and the scale of the change, has no 
precedent. It will require a phasing out of the old ﬁ  rst-
line regimen so as not to waste drugs and introducing the 
new regimen with all that this entails for patient and 
community understanding and healthcare delivery. 
Opera  tional research to carefully document such pro-
cesses will be essential so that lessons can be learnt for 
other countries embarking on the same course and for 
additional regimen changes in the future.
Conclusions
Lessons learnt
From the start of ART scale up six years ago, important 
lessons have been learnt. Table 1 gives an overview of the 
challenges, proposed way forward and the ways in which 
operational research can guide future policies. First, an 
increase in the number of diﬀ  erent ARV formulations has 
led to a more complicated PSM system and has increased 
the risks of stock outs. Th  e national ART programme 
therefore needs to maintain a careful balance between 
the optimization of individual care and a limited number 
of standard regimens to simplify and/or facilitate the 
supply management system.
Second, minimum national stock positions of ARVs of 
two months’ consumption often lead to very low stock 
positions in individual ART sites and additional work due 
to redistribution and repositioning of ARVs. National 
minimum stock positions should therefore increase. As 
the storage capacity for medicines at health facilities is 
limited and calculated based on stock positions of three 
months’ consumption, the most feasible option is there-
fore to increase the national storage capacity through the 
establishment of a central stock. Increasing the national 
stock positions in country to six months of consumption 
will allow supplies to arrive four months later than 
planned without causing supply interruption. Increasing 
the national stock position further would increase the 
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minimum national stock position from two months to six 
months of consumption would cost US$18 million on the 
basis of the non-stavudine-based ﬁ  rst-line ARV regimen.
Th  ird, increasing the frequency of deliveries from the 
central warehouse to ART sites would further decrease 
pressure on storage capacity in ART sites. Th  ese two 
measures would not only improve supply management of 
ARVs, but would also mitigate the eﬀ  ects of delays in 
grant disbursement.
Fourth, the supply management of ARVs is carried out 
by a few individuals who are not fully dedicated to this 
activity. Given the increasing volumes of ARVs and other 
HIV commodities, a dedicated full-time team of staﬀ   
experienced in supply management is needed to further 
develop the ARV PSM system and ensure its 
insti tutionalization.
Fifth, disbursement of grants needs to be streamlined.
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